![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire VICTORIA, BC, July 3...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders PR Newswire VICTORIA, BC, June 6, 2024 VICTORIA, BC, June 6, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 PR Newswire VICTORIA, BC, June 5, 2024...
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, May 23, 2024 Eight of nine patients...
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024 PR Newswire VICTORIA, BC, May 22, 2024...
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, May 21, 2024 Trial's first...
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting...
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire VICTORIA, BC, May 8, 2024 Eupraxia common shares now listed on the Nasdaq Capital...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.2849002849 | 3.51 | 3.56 | 3.25 | 22326 | 3.46912701 | CS |
4 | -0.15 | -4.1095890411 | 3.65 | 3.79 | 3.25 | 16440 | 3.59318075 | CS |
12 | -0.25 | -6.66666666667 | 3.75 | 4.12 | 3.25 | 25714 | 3.77869149 | CS |
26 | -2.12 | -37.7224199288 | 5.62 | 7.64 | 3.25 | 42886 | 4.45665768 | CS |
52 | -5.6 | -61.5384615385 | 9.1 | 9.1 | 3.25 | 33750 | 5.40196903 | CS |
156 | -0.6 | -14.6341463415 | 4.1 | 9.1 | 0.8 | 26823 | 4.17641415 | CS |
260 | -4.25 | -54.8387096774 | 7.75 | 9.1 | 0.8 | 26078 | 4.2702627 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions